Further research on AD-related biomarkers such as PET and/or CSF amyloid and tau measures, markers of vascular dementia, PD, Lewy body dementia (LBD) and other measures of neurodegeneration (eg, neurofilament light chain) may help to confirm the true rate of AD and other dementias in the schizophrenia population. The gene discussed is MAPT; the disease is schizophrenia.